Obagi Medical announced a collaboration with ProMD Health as part of the Aesthetics Leadership with Obagi’s Hyaluronic Acid Program. ProMD was selected for its strong multi-location network of 17 practices and its commitment to clinical excellence, making it an ideal evaluator to rigorously examine Obagi saypha MagIQ alongside comprehensive skincare protocols across its multi-state provider base. Through this collaboration, ProMD providers will participate in a structured evaluation of MagIQ across multiple practice locations. The program combines clinical education from Obagi national educators with hands on ProMD Health injector experience. The effort combines real world evaluation with an integrated skincare approach to further evidence-based advanced injection techniques and post-care protocols designed to deliver consistent, high-quality patient outcomes.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on WALD:
- Waldencast price target lowered to $2.50 from $3.50 at Alliance Global
- Waldencast price target lowered to $2 from $3 at Telsey Advisory
- Waldencast price target lowered to $2 from $4 at Canaccord
- Waldencast Posts Flat 2025 Results as Obagi Surges, Launches Strategic Review and Deleveraging Drive
- Waldencast reports Q4 revenue $72M vs. $72.1M last year